Steven Cohen’s Harvard Bioscience HBIO Stock Holding History

Steven Cohen’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,472	Closed	-$9.84K	–	4078
2025 Q4	$9.84K	Buy	+1,472	New	+$8.73K	﹤0.01%	3842

Other funds holding HBIO

WCM

Weber Capital Management San Francisco, California $118M AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steven Cohen's HBIO Position: Q1 2026 in Review

Steven Cohen sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 1,472 shares — an estimated $9.84K sold.

Steven Cohen first reported a position in HBIO in Q4 2025 and held it in 1 quarter. The position peaked at $9.84K in Q4 2025. 37 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

Steven Cohen reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
Steven Cohen sold 1,472 Harvard Bioscience shares in Q1 2026, an estimated $9.84K.
Steven Cohen first reported a position in Harvard Bioscience in Q4 2025 and held it in 1 quarter.
Steven Cohen's Harvard Bioscience position peaked at $9.84K in Q4 2025.
37 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.